separating the mass from the spinal cord. Dorsal roots appeared to be incorporated in the mass at numerous levels. There were no complications during the procedure, and pathology reports indicated that the mass was a cellular schwannoma (Fig. 3A) .
Postoperatively, the patient was transferred for inpatient spinal cord injury rehabilitation. At the 2-month followup, she had regained lower-extremity function and control of her bowel and bladder with marked improvement in her sensation. The physician and patient decided at that point that she should undergo excision of the second lesion to prevent the mass from causing problems similar to those caused by her thoracic lesion. After much counseling and discussion with the patient, a separate procedure was then carried out to excise the L3-4 lesion. Histological evaluation of this mass revealed a schwannoma with increased mitotic activity and focal necrosis (Fig. 3B) .
The patient had a full recovery from her 2 spine surgeries. However, 6 years after her initial presentation, she returned to the clinic with paresthesias and numbness of her left lower extremity. MRI at that time showed 3 separate lesions that had not been noted on previous images: a large, atypically heterogeneous enhancing lesion in the right psoas muscle adjacent to the right side of L4-5 ( Fig.  4A-C) , a lesion at the inferior aspect of the sacrococcygeal junction pushing slightly on the posterior wall of the rectum, and a lesion located in the left sciatic notch (Fig.  5 ). These lesions were not present on the earlier lumbar MR images.
The sciatic notch lesion was identified as the symptomatic lesion. However, given their accessibility through a single gluteal incision, both the sciatic notch and sacrococcygeal were excised. Both lesions were well demarcated and easily removed from the nerve sheath capsules. Again, histological analysis showed both tumors to be schwannomas (Fig. 3C) . Genetic testing at that time indicated that the patient possessed a somatic mutation at c.93G>A in exon 1 of the SMARCB1 gene.
Again, the patient recovered well from her procedure, and her symptoms abated. At follow-up, the patient had noted hyponasal speech and complained of increased drainage from her nose. An MR image showed a stable 5-mm schwannoma in the right Meckel's cave, dural thickening of the right falx in the frontal area, and a multilobulated, contrast-enhancing, cystic mass expanding the left maxillary and right maxillary and sphenoid sinuses. The mass did not invade the adjacent bone (Fig. 6 ). The patient had been having increasing nasal congestion and clear drainage bilaterally. A bilateral nasal endoscopy was performed [using a flexible endoscope] and showed narrow nasal cavities bilaterally with a pale gray mass in the right posterior nasal cavity.
The patient was returned to the operating room for endoscopic removal of her maxillary sinus masses. An endoscope was introduced into the patient's left nasal passage, and the lateral nasal wall was noted to be protruding medially. The uncinate process was then debrided, revealing a cystic capsule within the maxillary sinus. The cap- sule was then decompressed. Once the capsule had been decompressed, the remainder of the cystic structure was carefully removed (Fig. 7) . Attention was then turned to the right nasal passage where a similar procedure was performed. Histological analysis indicated the lesions to be schwannomas ( Fig. 3D and E) .
Four weeks later, the patient returned to the operating room for removal of a large L-4 nerve sheath tumor in her right psoas muscle, which was also found to be a schwannoma (Fig. 3F) . The patient tolerated the surgery very well and was discharged home from the hospital shortly after the procedure. Six weeks after surgery, the patient had recovered from surgery well. Because of her aggressive disease, further plans were made to follow up with the patient every 6 months with serial MRI. At her first 6-month appointment after her surgery, imaging showed a gross-total resection and no recurrence (Fig. 4D) . She was also noted to have no new lesions at that time. discussion Schwannomatosis is a rare disease characterized by the development of multiple schwannomas 11, 18, 22 and meningiomas. 14 The present case is a particularly aggressive case and is associated with a novel mutation in the SMARCB1 gene. In addition, this case highlights the variety of locations that these lesions can be found including, and also previously not described, in the maxillary and sphenoid sinuses. Coordination of multiple disciplines including neurosurgery, surgical oncology, otolaryngology, neurooncology, and genetics was necessary to optimize outcome for this case and to provide continued tumor surveillance.
Merker et al. found that 68% of patients with schwannomatosis experienced chronic pain.
14 These patients can also have symptoms of paresthesias, weakness, and muscle atrophy. 5 Our patient's presentation was no exception; she initially presented with bilateral weakness in her lower extremities. However, in contrast to the usual presentation, she also exhibited loss of bowel and bladder control, which was a result of late presentation and a severe spot of cord compression of the thoracic lesion.
Although peripheral nerve sheath tumors have a tendency to form in the head and neck, perinasal schwannomas are exceedingly rare, 2, 13, 20 with only 4% of these tumors occurring in these locations. 20 These tumors can arise from parasympathetic fibers of the sphenopalatine ganglion, sympathetic fibers of the carotid plexus, or branches of the ophthalmic and maxillary divisions of the trigeminal nerve. 3 To our knowledge, this is the first reported account of a perinasal schwannoma occurring in a patient with schwannomatosis.
Another unique quality of this case is the patient's unique mutation of SMARCB1. The patient has a family history that is negative for neurofibromatosis Type 1 or 2 or schwannomatosis. The sporadic origin in this case is consistent with the approximately 90% of de novo mutations seen in schwannomatosis. 8, 21 This specific mutation, c.93G>A in exon 1 has not previously been described (Fig.  8) . Similar gene mutations have, however, been reported in cases of rhabdoid tumors, 1,7 but, to our knowledge, this mutation has not been previously described in the schwannomatosis literature.
The SMARCB1 gene is a tumor suppressor gene located on chromosome 22. 3, 6, 10 This gene spans 47,554 base pairs and includes 9 exons that code a protein that is a subunit of an adenosine triphosphate-dependent chromatin-remodeling complex that relaxes regions of chromatin and allows transcription to occur. Loss of this SMARCB1 gene function results in chromosomal instability and polyploidy in rhabdoid tumors. 1, 17 Mutations in this gene are also responsible for around 50% of familial schwannomatosis and 10% of sporadic schwannomatosis. 16 The exact mechanisms by which these mutations cause schwannomatosis are not well understood. Sestini et al. described a 4-hit mechanism involving the genes SMARCB1 and NF2 in the development of schwannomatosis. 19 There have also been reports of LZTR1 being involved in a large number of schwannomatosis cases.
15, 16 Hutter et al., after sequencing the schwannomatosis exome, suggested that even more gene mutations on chromosome 22 must exist to account for the cases of schwannomatosis when SMARCB1 and LZTR1 are excluded. 8 Zhang et al. reported that perhaps mutations in COQ6 play a role in schwannomatosis development. 24 
conclusions
To our knowledge, we present the first case of paranasal schwannomas occurring in schwannomatosis as well as the first reported mutation of c.93G>A in exon 1 of the SMARCB1 gene. This case demonstrates the complexity of schwannomatosis treatment, symptomatology, and genetics.
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